IP Library Granted Patent US 7,456,268
Granted Patent B2
US 7,456,268 · App. 11/868,794 · Granted Nov 25, 2008

Materials and methods for inhibiting Wip1

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,456,268
App. No.
11/868,794
Granted
Nov 25, 2008
Kind
B2
Abstract

Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, comprising administering to the mammal a cancer-treating effective amount of a Wip1 inhibitor; a method of screening an oligonucleotide or morpholino oligomer for the ability to inhibit the expression of Wip1; a method of determining the efficacy with which a test oligonucleotide or morpholino oligomer inhibits Wip1 expression; a method of screening a compound for Wip1-inhibiting activity; and a method of determining the efficacy with which a test compound inhibits Wip1.

Claims (2)

1. An isolated or purified oligonucleotide consisting essentially of the nucleotide sequence of SEQ ID NO: 1.

2. An isolated or purified morpholino oligomer consisting essentially of the sequence of SEQ ID NO: 1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2007
From: BULAVIN, DMITRY; APPELLA, ETTORE; FORNACE, ALBERT J., JR.; KALLIONIEMI, ANNE
To: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 019931/0188 →